United States· US:0169-4130_852fff2d-704e-4b01-9244-439a28094202
Ozempic
A medicinal product containing semaglutide, registered in United States by Novo Nordisk Pharmaceutical Industries, LP.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- semaglutide
- Manufacturer
- Novo Nordisk Pharmaceutical Industries, LP
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1101694130131 SYRINGE, PLASTIC in 1 CARTON (0169-4130-13) / 3 mL in 1 SYRINGE, PLASTIC (0169-4130-01)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Semaglutide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKAYSHILDNovo Nordisk A/S, Bagsvaerd
- FinlandKayshildNovo Nordisk A/S
- PolandKayshildNovo Nordisk A/S
- BelgiumKayshild 0.25 mgNovo Nordisk
- SwedenKayshild 0,25 mg Injektionsvätska, lösning i förfylld injektionspennaNovo Nordisk A/S
- SpainOZEMPIC 0,25 MG SOLUCION INYECTABLE EN PLUMA PRECARGADANovo Nordisk A/S
- IrelandKayshild 0.25 mg solution for injection in pre-filled penNovo Nordisk A/S
- NetherlandsKayshild 0,25 mg oplossing voor injectie in een voorgevulde penNovo Nordisk A.S.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kayshild, Ozempic
- Norway · Kayshild, Ozempic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/90d33da3-62b8-41e2-bc8f-cdcbf87f819a GET /v1/drugs/90d33da3-62b8-41e2-bc8f-cdcbf87f819a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 4
},
"productid": "0169-4130_852fff2d-704e-4b01-9244-439a28094202",
"productndc": "0169-4130",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "SEMAGLUTIDE",
"proprietary_name": "Ozempic",
"active_ingred_unit": "mg/mL",
"application_number": "NDA209637",
"marketing_category": "NDA",
"nonproprietary_name": "semaglutide",
"start_marketing_date": "20200930",
"active_numerator_strength": "1.34"
}See everything about semaglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.